Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands

Journal of Molecular Biology
J RahuelB Gay

Abstract

An anthranyl moiety placed at the N terminus of a phosphotyrosine peptide potentiates the inhibitory effect of this small peptide on the binding of the Grb2 SH2 domain to the EGF receptor. Using molecular modeling procedures based on the Lck SH2 domain structure, this observation was rationalized in terms of a suitably favorable pi-pi stacking interaction between the anthranyl moiety and the arginine alphaA2 (ArgalphaA2) residue side-chain of Grb2 SH2. The crystal structure of the Grb2 SH2 domain in complex with the inhibitor 2-Abz-EpYINQ-NH2 (IC50 26 nM) has been solved in two different crystal forms at 2.1 and 1.8 A resolution. This structure confirms the modeling based on the Lck SH2 domain. The ArgalphaA2 residue is conserved in most SH2 domains. Thus, as expected, the anthranyl group also confers high affinity to small peptide ligands of other SH2 domains such as Lck-, PLC-gamma-amino-terminal and p85 amino-terminal SH2 domains as demonstrated by structure affinity relationships (SAR) data. These potent peptides with an amino-terminal surrogate group and the structure of Grb2 SH2 domain in complex with one such peptide represent good starting points for the design and optimization of new inhibitors of many SH2 domains.

References

Mar 1, 1991·Acta Crystallographica. Section A, Foundations of Crystallography·T A JonesM Kjeldgaard
Aug 1, 1994·Molecular and Cellular Biology·A G BatzerJ Schlessinger
Jan 1, 1994·Cold Spring Harbor Symposia on Quantitative Biology·J Schlessinger, D Bar-Sagi
Jan 31, 1994·FEBS Letters·J Downward
Jun 1, 1995·Protein Engineering·M J ZvelebilM D Waterfield
Jul 1, 1996·Nature Structural Biology·J RahuelM G Grütter
Jan 1, 1993·Trends in Cell Biology·B J Mayer, D Baltimore
Sep 1, 1994·Acta Crystallographica. Section D, Biological Crystallography·UNKNOWN Collaborative Computational Project, Number 4

❮ Previous
Next ❯

Citations

Oct 15, 2010·Acta Crystallographica. Section D, Biological Crystallography·John H ClementsStephen F Martin
May 1, 2007·Archives of Biochemistry and Biophysics·Aaron P BenfieldStephen F Martin
Apr 5, 2003·Protein Engineering·Fabrizio Giordanetto, Romano T Kroemer
Sep 27, 2006·Angewandte Chemie·Aaron P BenfieldStephen F Martin
Dec 1, 2005·Anti-cancer Drugs·Pathirage G DharmawardanaDonald P Bottaro
Mar 1, 2006·International Journal of Peptide Research and Therapeutics·Terrence R Burke
Mar 30, 2019·Biophysics and Physicobiology·Yuhi HosoeMasayuki Oda
Jul 5, 2001·The Journal of Peptide Research : Official Journal of the American Peptide Society·F D LungS Wang
Jun 3, 2005·Protein Science : a Publication of the Protein Society·Monika IvancicBarbara A Lyons
Feb 24, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Huang ShaoDavid J Tweardy
Feb 12, 2013·Chemical Society Reviews·Dziyana KraskouskayaPatrick T Gunning
Oct 30, 2001·Critical Reviews in Oncology/hematology·M VidalC Garbay
Mar 26, 1999·Bioorganic & Medicinal Chemistry Letters·T R BurkeD Yang
Feb 1, 2005·Biochimica Et Biophysica Acta·Kazuya Machida, Bruce J Mayer
Jan 14, 2012·ACS Chemical Biology·Katsunori TanakaKoichi Fukase
Jul 13, 2001·Journal of Medicinal Chemistry·J R ProudfootM Llinas-Brunet

❮ Previous
Next ❯

Related Concepts

Related Feeds

BK Virus Infection

BK virus infection is a significant complication of modern immunosuppression used in kidney transplantation. Discover the latest research on BK virus infection here.